235 East 42nd Street
About Pfizer, Inc.
At Pfizer Worldwide Research & Development (WRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing critical medicines and treatments for patients around the world.
Pfizer’s OWNIT! Culture
Through Pfizer’s shared mission to impact global health, Pfizer has built a unique OWNIT! culture to empower you to play your part in each of Pfizer’s life-changing achievements. So what does OWNIT! mean? It means taking ownership of your career and the contribution you make to the business and the patients and customers impacted by Pfizer’s business. This encouragement for personal progress allows colleagues to treat each other with honesty and respect, to act quickly and decisively, all to deliver results with commitment and care.
Professional Development at Pfizer
Pfizer’s belief that every person matters is also what proves their commitment to you. Whatever your talent or skill, you will be taught how to become an expert in your field through tools like Pfizer’s Mentor Match online tool and creating detailed career “roadmaps” with your manager that take into account your interests and aspirations as well as Pfizer’s business needs. Managers are also encouraged to provide frequent performance feedback instead of relying solely on yearly evaluations. From here, you’ll be inspired to refine – and redefine – your personal and professional goals.
Diversity at Pfizer
Pfizer believes that diversity is just as crucial to building a successful business as it is to building a vibrant culture. Pfizer’s community is one of the greatest building aspects about their culture. And their Diversity and Inclusion team ensures that every colleague experiences a fair and supportive environment. From holding managers and leaders accountable for creating inclusive and equitable workplaces, to helping colleagues appreciate the value of diversity, Pfizer is a place where people from all backgrounds and abilities can build a fulfilling career and reach their full potential.
Finding Your Community and Making a Difference
With more than 95 Colleague Resource Groups (CRGs) located around the world, working at Pfizer means finding a community. Pfizer offers CRGs focused on the following groups: Asians, Blacks, colleagues with disabilities, Latinos, LGBTQ, Veterans and Women. These CRGs offer support, mentoring and networking opportunities to help members enhance their skills and advance their careers. They also help their communities by participating in volunteer and philanthropic activities, from sponsoring student scholarships to health fairs focused on the unique healthcare concerns of diverse populations.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of today. As one of the world’s premier pharmaceuticals companies, Pfizer’s network and influence spans the entire globe. But in every country and continent, Pfizer colleagues are energized by a unique spirit. No matter the role or responsibility, colleagues are empowered by the belief that the work they do has a direct impact on patients.
3976 articles with Pfizer, Inc.
First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and 1% Operational Growth From Upjohn
Pfizer closed out the first quarter of 2019 with revenues of $13.1 billion driven by a significant 36 percent global growth of Eliquis sales, a 34 percent increase in Xeljanz revenue and a 25 percent increase in sales of Ibrance, the company announced this morning.
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, be granted marketing authorization in the European Union (EU).
Senate President, Speaker of the House, Leaders of Legislation, Medicine and Advocacy Join Forces to Lead the Nation in Recognizing Prostate Cancer as a Public Health Priority and Leading Disparity
AdMeTech Foundation's 11th Annual Prostate Cancer Awareness Day at the State House Highlights Massachusetts Model of National Leadership in Public Awareness, Education and Research
Declares 36-Cent Second-Quarter 2019 Dividend
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
Renal cell carcinoma is also called renal cell cancer or renal cell adenocarcinoma. Approximately 90% of all kidney cancers are renal cell carcinomas.
Pfizer and Eli Lilly and Company announced top-line results from a Phase III clinical trial of two doses of tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee.
4/19/2019Possibly in response to a trend for Medicare-for-All initiatives, healthcare stocks plunged this week. This largely affected companies like UnitedHealth, which fell 3.2%, Anthem, dropping by 6.8%, and Cigna Corp., sliding 5.1%.
Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019.
SwitchPoint 2019 to Tackle Global Health Impacts of Misinformation, Immersive Tech, African Innovation and More
Humanitarian experts and innovators from around the world will gather April 25 and 26 in Saxapahaw, North Carolina, for IntraHealth International's annual SwitchPoint conference.
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
The Biologics License Application is expected to be submitted to the U.S. FDA by the end of 2020, subject to the successful completion of Phase 3 studies
Only a few weeks after Concerto HealthAI inked a deal with Bristol-Myers Squibb, it has signed a similar deal with Pfizer.
“Men with breast cancer have limited treatment options, making access to medicines such as Ibrance critically important,” stated Bret Miller, founder of the Male Breast Cancer Coalition.
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Approval of expanded indication based predominately on real-world data
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer-related death worldwide and despite advances in biomarker-driven therapies, overcoming resistance continues to be crucial in treating EGFR-mutated non-small cell lung cancer
Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.